GlaxoSmithKline sues Roche/Genentech alleging Herceptin patent infringements; updates on Relovair Ph II development with Theravance

23 September 2010

UK pharmaceutical giant GlaxoSmithKline (LSE: GSK) has filed a law suit in the USA against Swiss drug major Roche (ROG.VX), claiming it made antibodies, including Roche's blockbuster cancer drug Herceptin (trastuzumab) – which generated first-half 2010 sales of around $2.78 for the Swiss group, that infringed two of its patents, according to a batch of news reports including from Dow Jones and Swiss Info.

According to a filing in Delaware District Court, GSK claims Roche made therapeutic antibody products, "including without limitation Herceptin," that infringed two of its patents, which deal with antibody purification. GSK is seeking unspecified damages.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK